Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk

Narcolepsy results from immune-mediated destruction of hypocretin secreting neurons in hypothalamus, however the triggers and disease mechanisms are poorly understood. Vaccine-attributable risk of narcolepsy reported so far with the AS03 adjuvanted H1N1 vaccination Pandemrix has been manifold compar...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 9; no. 12; p. e114361
Main Authors Vaarala, Outi, Vuorela, Arja, Partinen, Markku, Baumann, Marc, Freitag, Tobias L, Meri, Seppo, Saavalainen, Päivi, Jauhiainen, Matti, Soliymani, Rabah, Kirjavainen, Turkka, Olsen, Päivi, Saarenpää-Heikkilä, Outi, Rouvinen, Juha, Roivainen, Merja, Nohynek, Hanna, Jokinen, Jukka, Julkunen, Ilkka, Kilpi, Terhi
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 15.12.2014
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Narcolepsy results from immune-mediated destruction of hypocretin secreting neurons in hypothalamus, however the triggers and disease mechanisms are poorly understood. Vaccine-attributable risk of narcolepsy reported so far with the AS03 adjuvanted H1N1 vaccination Pandemrix has been manifold compared to the AS03 adjuvanted Arepanrix, which contained differently produced H1N1 viral antigen preparation. Hence, antigenic differences and antibody response to these vaccines were investigated. Increased circulating IgG-antibody levels to Pandemrix H1N1 antigen were found in 47 children with Pandemrix-associated narcolepsy when compared to 57 healthy children vaccinated with Pandemrix. H1N1 antigen of Arepanrix inhibited poorly these antibodies indicating antigenic difference between Arepanrix and Pandemrix. High-resolution gel electrophoresis quantitation and mass spectrometry identification analyses revealed higher amounts of structurally altered viral nucleoprotein (NP) in Pandemrix. Increased antibody levels to hemagglutinin (HA) and NP, particularly to detergent treated NP, was seen in narcolepsy. Higher levels of antibodies to NP were found in children with DQB1*06:02 risk allele and in DQB1*06:02 transgenic mice immunized with Pandemrix when compared to controls. This work identified 1) higher amounts of structurally altered viral NP in Pandemrix than in Arepanrix, 2) detergent-induced antigenic changes of viral NP, that are recognized by antibodies from children with narcolepsy, and 3) increased antibody response to NP in association of DQB1*06:02 risk allele of narcolepsy. These findings provide a link between Pandemrix and narcolepsy. Although detailed mechanisms of Pandemrix in narcolepsy remain elusive, our results move the focus from adjuvant(s) onto the H1N1 viral proteins.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: HN received honoraria for technical consultancy from GlaxoSmithKline (GSK), and Pfizer for development of pneumococcal conjugate vaccines. JJ is co-investigator of a nationwide effectiveness study of the ten-valent pneumococcal conjugate vaccine mainly funded by GlaxoSmithKline. MP has been consultant for Bioprojet and UCB Pharma and received funding support and honoraries for lecturing from Bioprojet, GSK, Cephalon, and Leiras/Takeda. T. Kilpi is principal investigator of a nationwide effectiveness study of the ten-valent pneumococcal conjugate vaccine mainly funded by GlaxoSmithKline, and her unit received funding for a clinical trial on the safety and immunogenicity of a prototype pandemic influenza vaccine from Solvay Pharmaceuticals. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. All other authors confirm they have no conflicts of interest. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: OV AV MB MJ JR TLF SM. Performed the experiments: OV AV MB MJ TLF IJ MR RS. Analyzed the data: OV AV PS MB MJ TLF JJ. Contributed reagents/materials/analysis tools: MP PO TK OSH. Wrote the paper: OV AV MB MJ JR TLF SM IJ TK HN JJ MP.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0114361